drugset / Trial / NCT03492710
Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency
NaSingle-groupOpen-labelTreatment
Summary
To assess the safety, efficacy, and pharmacokinetics of IGIV-SN in pediatric subjects with primary immunodeficiency humoral diseases (PHID)
Timeline
- Start
- 2019-04-30
- Primary completion
- 2019-04-30
- Completion
- 2019-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 5 g | — |
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 10 g | — |